16 results about "Hyperammonemia" patented technology

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).

To provide a composition for preventing, ameliorating or treating a disease caused by protein nitration comprising a peptide with terminal tyrosine as an effective component.SOLUTION: A peptide with terminal tyrosine has an excellent effect of inhibiting protein nitration and also an excellent effect of preventing, ameliorating or treating disease symptoms in chronic immobilization stress-induced depression / cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.SELECTED DRAWING: None

The invention provides an application of a component A as or used for preparing an SIRT5 inducer, the component A at least comprises one or more than two of ergothioneine, ectoine and hyaluronic acid or salt thereof, and the component A can be used for the SIRT5 inducer or used for preparing an SIRT5 expression inducer, so that cell aging can be inhibited, and the SIRT5 inducer can be used for preparing an SIRT5 expression inducer. The traditional Chinese medicine composition is used for improving natural skin aging, cardiac hypertrophy and / or hyperammonemia.

A method for ameliorating a disease caused by nitration of tyrosine in protein includes administering a composition comprising tyrosine or a salt thereof to a subject in need thereof. Tyrosine as effective component of the present invention not only can enhance the activity of glutamine synthetase having reduced activity and but also has an effect of restoring the amount (i.e., ratio) of glutamine and glutamic acid in brain and the amount of ammonia to normal level, an effect of enhancing the insulin sensitivity in a model of type 2 diabetes, an effect of suppressing the excitotoxicity and oxidative stress in a model of epileptic seizure, an effect of reducing cerebral infarction and enhancing the activity of GS in a model of brain stroke, an effect of eliminating the nitration of tyrosine using human recombinant MnSOD, and an effect for acute renal failure and hyperammonemia.

The present disclosure provides a use of a liposomal suspension comprising transmembrane pH-gradient liposomes, for the treatment of an acute hyperammonemia episode (HAC) associated with inborn errors of metabolism (IEM) in a subject, wherein the treatment comprises intraperitoneally administering the liposomal suspension to the subject and removing a dialysate containing ammonia-loaded liposomes from the subject.

To provide a pharmaceutical composition for treating or preventing hyperammonemia and hepatic encephalopathy.SOLUTION: A pharmaceutical composition for treating or preventing hyperammonemia contains rifaximin and conjugated bile acid.SELECTED DRAWING: None

The present disclosure provides implantable engineered tissue constructs having hepatocytes and stromal cells for the treatment of hyperammonemia.

The peptide with tyrosine at the terminal has an excellent effect of inhibiting protein nitration; the composition has an excellent effect of preventing, improving or treating disease symptoms in a chronic body-bound stress depression / cognitive disorder inducing model, an Alzheimer disease dementia model, an epileptic seizure model, a cerebral apoplexy model, a type 2 diabetes mellitus model, an acute renal failure model or a hyperammonemia model.

The invention discloses a composite hydrogel system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: jointly encapsulating chlorella and sodium phenylbutyrate in semi-interpenetrating network hydrogel formed by cross-linking carboxymethyl chitosan and sodium alginate through genipin, so as to prepare a composite hydrogel system with an oral administration function. The hydrogel system has good colon targeted release characteristics and pH responsiveness, can prolong the retention time of drugs in gastrointestinal tracts, protects chlorella from being damaged by gastric acid and enzymolysis, realizes dual-channel removal of ammonia, and effectively inhibits growth of colorectal cancer. The system can regulate intestinal microbiota, enrich beneficial bacteria such as ackermann muciniphile and improve the intestinal microenvironment. The hydrogel system is good in biocompatibility, high in long-term oral administration safety, wide in raw material source, low in cost, simple in preparation process and easy for large-scale production, and has an important clinical application prospect in the field of combined treatment of hyperammonemia and colorectal cancer.

The present disclosure provides use of a liposomal suspension comprising transmembrane pH gradient liposomes for the treatment of acute hyperammonemic episodes (HAC) associated with an inborn error of metabolism (IEM) in a subject, the treatment comprising intraperitoneally administering the liposomal suspension to the subject and removing dialysate containing ammoniated liposomes from the subject.

The invention relates to an application of a jasminum grandiflorum extract in preparation of a medicine for treating and / or preventing hepatic encephalopathy, belonging to the technical field of biological medicines. The invention provides an application of oleuropein in preparation of a medicine for treating and / or preventing hyperamminemia related diseases. The invention provides an application of a jasminum grandiflorum extract in preparation of a medicine for treating and / or preventing diseases related to hyperamniemia and further provides a medicine composition for treating and / or preventing the diseases related to the hyperamniemia, and the medicine composition comprises oleuropein or the jasminum grandiflorum extract and pharmaceutically acceptable auxiliary materials. Experiments prove that the jasminum grandiflorum extract or oleuropein can remarkably reduce the blood ammonia and brain ammonia levels of mice with acute liver injury and relieve pathological states such as astrocyte swelling caused by hyperammoemia, has the effects of reducing blood ammonia and brain ammonia, and can be used for treating hyperammoemia.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a mangnolia officinalis extract or a structural analogue thereof in preparation of a medicament for treating hyperinsulinemia / hyperamminemia syndrome. The invention provides a new application of a mangnolia officinalis extract represented by honokiol. Research shows that the mangnolia officinalis extract or the structural analogue thereof can well inhibit the activity of glutamate dehydrogenase (GDH), including wild type GDH and GDH capable of causing acquisition function mutation of the hyperinsulinemia / hyperamminemia (HI / HA) syndrome, so that the effect of the mangnolia officinalis extract or the structural analogue thereof as a GDH inhibitor in treatment of the HI / HA syndrome is expanded, and the application of the mangnolia officinalis extract or the structural analogue thereof in treatment of the HI / HA syndrome is promoted. Effective attempts are made for solving the problem that existing medicines for treating the rare HI / HA syndrome are rare, the current situation of treating the HI / HA syndrome can be remarkably improved, the situation of lack of targeted medicines is broken through, the life quality of patients is improved, and the family and social burden of the patients is greatly relieved.

The invention belongs to the technical field of biological medicines, and relates to application of a histone deacetylase inhibitor HDACi in preparation of a medicine for preventing and / or treating hyperammonemia-induced encephalopathy. According to the invention, a histone deacetylase inhibitor HDACi is used as a new medicine, the HDACi can enter a central nervous system, and the GS is triggered to be degraded through a proteasome mediated by CRBN E3 ubiquitin ligase by improving the acetylation level of a key enzyme, namely glutamine synthetase (GS), of astrocytes, so that the GS protein abundance is reversibly reduced, and the GS protein abundance is reduced. The application has the advantages that pathological accumulation of toxic metabolite glutamine can be reduced from the source, cerebral edema, autophagy-lysosomal dysfunction, neuroinflammation and neuron injury caused by the pathological accumulation can be synchronously improved, severe neurotoxicity such as persistent enzyme inhibition and acute epilepsy caused by irreversible inhibitors such as MSO can be avoided, clinical transformation risks can be obviously reduced, and the safety is high.

The application relates to the field of biological medicine, in particular to application of sodium tiglate in preparation of products for promoting liver regeneration and reducing blood ammonia; it is found and disclosed for the first time in the application that sodium tiglate can be applied to preparation of liver regeneration or liver function recovery products, liver cell proliferation capacity of residual liver after partial hepatectomy can be improved by using sodium tiglate, blood ammonia level after liver surgery is controlled, nitrogen metabolism disorder is improved by promoting conversion of blood ammonia into urea, and liver cell regeneration capacity is improved; the application of sodium tiglate provides a new treatment strategy with clear action mechanism and wide development prospect for treatment of insufficient liver regeneration after partial hepatectomy and hyperammonemia.